← Back to Screener
CNS Pharmaceuticals, Inc. Common Stock (CNSP)
Price$5.24
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-41.65%
Price vs S&P 500 (4W)-36.14%
VGM Score48.47
Market Capitalization$7.19M
All Metrics
Book Value / Share (Quarterly)$0.09
P/TBV (Annual)1.54x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-18.79
Price vs S&P 500 (YTD)-17.67%
EPS (TTM)$-29.17
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-29.17
EPS (Annual)$-35.75
ROI (Annual)-326.74%
Cash / Share (Quarterly)$3.64
ROA (Last FY)-183.81%
EBITD / Share (TTM)$-29.96
ROE (5Y Avg)-216.41%
Cash Flow / Share (Annual)$-21.86
P/B Ratio101.70x
P/B Ratio (Quarterly)27.43x
Net Income / Employee (Annual)$-1,981,300
Net Interest Coverage (TTM)-1526.00x
ROA (TTM)-164.21%
EPS Incl Extra (Annual)$-35.75
Current Ratio (Annual)1.98x
Quick Ratio (Quarterly)0.65x
3-Month Avg Trading Volume1.00M
52-Week Price Return-59.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.41
52-Week High$12.96
EPS Excl Extra (Annual)$-35.75
CapEx CAGR (5Y)-1.89%
26-Week Price Return-28.07%
Quick Ratio (Annual)1.77x
13-Week Price Return57.19%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)0.89x
Enterprise Value$4.47M
Book Value / Share Growth (5Y)-12.35%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$11.38
3-Month Return Std Dev481.85%
Net Income / Employee (TTM)$-2,060,200
ROE (Last FY)-350.48%
Net Interest Coverage (Annual)-968.35x
EPS Basic Excl Extra (Annual)$-35.75
Total Debt / Equity (Quarterly)3.29x
EPS Incl Extra (TTM)$-29.17
ROI (TTM)-233.65%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.03
Price vs S&P 500 (52W)-87.15%
Year-to-Date Return-6.29%
5-Day Price Return-3.91%
EPS Normalized (Annual)$-35.75
ROA (5Y Avg)-349.09%
Month-to-Date Return-9.56%
Cash Flow / Share (TTM)$-6.63
EBITD / Share (Annual)$-36.05
ROI (5Y Avg)-204.23%
EPS Basic Excl Extra (TTM)$-29.17
P/B Ratio (Annual)0.72x
Book Value / Share (Annual)$7.15
Price vs S&P 500 (13W)46.53%
Beta1.06x
Revenue / Share (TTM)$0.00
ROE (TTM)-239.70%
52-Week Low$1.90
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-7.30est. -5.48
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNSPCNS Pharmaceuticals, Inc. Common Stock | — | — | C | $5.24 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
CNS Pharmaceuticals is a clinical-stage biopharmaceutical company developing anticancer therapies for brain and central nervous system tumors. The company's lead candidate, Berubicin, is in development for glioblastoma, an aggressive form of primary brain cancer with limited treatment options. The company aims to address significant unmet medical needs in oncology.